Inventiva reports loss for 2016 due to R&D activities
March 27, 2017Inventiva, a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, has reported its financial results for the year ended December 31, 2016.
The company has reported €7 million loss for the 2016, which is increase comparing the last year’s loss of €8,8 million.
The company’s R&D expenditure amounted to €22.1 million increasing by 12.8%. Efforts continue to be focused primarily on external studies relating to the three clinical development programs, the company said.
“2017 already looks like another year of strong achievements, in particular with the continuation of IVA337 clinical trials in NASH and systemic sclerosis, the recruitment of the first patient for IVA336 trial in MPS VI and the expected achievement of major milestones in our two collaborations with AbbVie and Boehringer Ingelheim,” added Pierre Broqua, CSO and co-founder of Inventiva.
